This study identified SLC5A3 as an associated factor and a pathological hallmark in IBM, and proposes osmolyte pathway intervention as an alternative approach to be further explored for future therapeutic management for this currently incurable disorder. Here, SLC5A3 is linked to inclusion body myositis.